EUVIMEDEUVIMED entdecken
Open Access

Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with 89 Zr-PD-L1x4-1BB bispecific Mabcalin tumor uptake

Claudia A J van Winkel, Xiaoyu Fan, Danique Giesen, Glenn Gauderat, Steven de Jong, Thomas Jaquin, Wim Timens, Agathe Lepissier, Marleen Richter, Stefan Grüner, Nicole Andersen, Laurent Laboureur und 5 weitere

Theranostics · 22.04.2026 · 16 (11) · 6184-6201

DOI: 10.7150/thno.123930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 22.04.2026. Verfasst von Claudia A J van Winkel und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Radioisotopes, Zirconium, B7-H1 Antigen, Tumor Necrosis Factor Receptor Superfamily, Member 9. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antibody-anticalin fusion protein (Mabcalin) targeting programmed cell death-ligand 1 (PD-L1) and T-cell costimulatory immunoreceptor CD137 (4-1BB) is designed to enhance T-cell reactivity while preventing T-cell inhibition by PD-L1/programmed cell death protein 1 (PD-1) checkpoint blockade. Using positron emission tomography (PET) imaging and ex vivo analysis, we investigated the factors influencing biodistribution, tumor uptake, and the influence of dose and target presence.

Methods

Murine or human PD-L1-reactive and human 4-1BB reactive Mabcalins (mPD-L1xh4-1BB and hPD-L1xh4-1BB) were generated, radiolabeled with 89Zr, and administered to human 4-1BB knock-in (h4-1BB KI) or wild-type (WT) mice bearing PD-L1-positive mouse MC38 tumors. Mice underwent serial PET imaging on days 1, 2, and 4 or on days 2, 4, and 7 post intravenous injection, followed by ex vivo biodistribution. The intratumoral distribution of 2 protein doses of 89Zr-radiolabeled mPD-L1xh4-1BB and hPD-L1xh4-1BB was examined using autoradiography on tumor tissue sections. These tumor sections were immunohistochemically stained for PD-L1, CD3, CD8, and 4-1BB to link uptake to target expression levels.

Results

89Zr-mPD-L1xh4-1BB, able to bind mPD-L1 and h4-1BB in h4-1BB KI mice, predominantly showed specific and rapid dose-dependent lymphoid tissue uptake. The tumor uptake of 200 µg 89Zr-mPD-L1xh4-1BB in h4-1BB KI mice was also specific and increased over time. Tumor uptake in this group, where both targets PD-L1 and 4-1BB could be bound, was > 4-fold higher than in the groups that could bind only PD-L1 or 4-1BB. Dual PD-L1 and 4-1BB Mabcalin engagement at a therapeutic dose also resulted in elevated tumor protein expression levels for PD-L1, CD3, and CD8, which were lower when only PD-L1 or 4-1BB was engaged. The lowest expression was observed with the Mabcalin binding non-specifically (Ptrend≤0.01 for PD-L1 and CD3, Ptrend≤0.05 for CD8).

Conclusion

The biodistribution of mPD-L1xh4-1BB is specific, dose-dependent, and associated with the elevated target expression resulting from dual PD-L1 and 4-1BB engagement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadioisotopesZirconiumB7-H1 AntigenTumor Necrosis Factor Receptor Superfamily, Member 9Antibodies, BispecificAntibodies, MonoclonalAnimalsMiceHumansPositron-Emission TomographyTissue DistributionCell Line, TumorFemaleT-Lymphocytes

Stichwörter der Autor:innen

PET imagingbiodistributionbispecific antibodiescancer immunotherapypharmacokinetics

Substanzen

RadioisotopesZirconium-89ZirconiumB7-H1 AntigenTumor Necrosis Factor Receptor Superfamily, Member 9Antibodies, BispecificCD274 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Medical Oncology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • R&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
  • Pieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
  • Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.

Zitieren

APA

van Winkel, C. A. J., Fan, X., Giesen, D., Gauderat, G., de Jong, S., Jaquin, T., Timens, W., Lepissier, A., Richter, M., Grüner, S., Andersen, N., Laboureur, L., Pattarini, L., Lelièvre, H., de Vries, E. G. E., Morales-Kastresana, A., & Hooge, M. N. L. (2026). Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with 89 Zr-PD-L1x4-1BB bispecific Mabcalin tumor uptake. Theranostics, 16(11), 6184-6201. https://doi.org/10.7150/thno.123930

Vancouver

van Winkel CAJ, Fan X, Giesen D, Gauderat G, de Jong S, Jaquin T, et al. Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with 89 Zr-PD-L1x4-1BB bispecific Mabcalin tumor uptake. Theranostics. 2026;16(11):6184-6201. doi:10.7150/thno.123930

BibTeX
@article{vanWinkel2026,
  author = {van Winkel, Claudia A J and Fan, Xiaoyu and Giesen, Danique and Gauderat, Glenn and de Jong, Steven and Jaquin, Thomas and Timens, Wim and Lepissier, Agathe and Richter, Marleen and Grüner, Stefan and Andersen, Nicole and Laboureur, Laurent and Pattarini, Lucia and Lelièvre, Helene and de Vries, Elisabeth G E and Morales-Kastresana, Aizea and Hooge, Marjolijn N Lub-de},
  title = {Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with 89 Zr-PD-L1x4-1BB bispecific Mabcalin tumor uptake},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {6184--6201},
  doi = {10.7150/thno.123930}
}
Kostenlos starten →